
Patient-led research and advocacy for #LongCovid and infection-associated chronic conditions!
- Tweets3.9K
- Following694
- Followers26.3K
- Likes4.2K

ALT Infographic by the COVID-19 Longhauler Advocacy Project (C19LAP) titled “We Met with Shionogi to Answer Your Questions About Access to XOCOVA.” What is XOCOVA? An antiviral used for COVID-19 post-exposure prophylaxis (PEP), unlike Paxlovid, which treats infection. The graphic reports a 67% reduction in severe COVID-19 and 34% reduction in transmission. The RESILIENCE and UCSF studies investigate Long COVID prevention and treatment. Accessing XOCOVA: No positive test or proof of another person's infection is required; close contact with someone with COVID-19 is sufficient. Available for ages 12 and older, subject to clinician and insurer requirements. Pharmacies can order it through distributors. Insurance coverage varies, with commercial copay assistance and patient assistance programs available. Barriers: Limited testing, delays within the 72-hour treatment window, clinician bias, drug interactions, and affordability. More information: www.xocova.com or 877-4XOCOVA.












